# Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

> **NCT07130643** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xinhong Wu, PhD** · enrollment: 40 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** CDK4/6 inhibitors+Endocrine Therapy

## Key facts

- **NCT ID:** NCT07130643
- **Lead sponsor:** Xinhong Wu, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-06-20
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130643, "Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07130643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*